// App-Quantinova.ai

2791 : Hypoxia selectively confers resistance to the survivin-targeting compound YM155 in acute myeloid leukemia and Ewings sarcoma cell lines

Researchers

Presenter

  • Justin Montoya

Principal Investigators

  • Kieran Finch

  • Jan Simper

  • Robert J. Arceci

  • Eiman A. Aleem

Medical Centers

  • Phoenix Children's Hospital & UA College of Medicine-Phoenix, Phoenix, AZ

  • UA College of Medicine-Phoenix, Phoenix, AZ

  • Arizona State University, Phoenix, AZ

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

  • Mismatch repair deficiency

  • Solid malignancies

  • Sarcoma

Biomarkers

  • N/A

Drug/Treatment

  • YM155

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved